Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Equity Ratio: 2010-2024

Historic Equity Ratio for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to 0.76.

  • Anika Therapeutics' Equity Ratio fell 0.30% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 0.30%. This contributed to the annual value of 0.76 for FY2024, which is 3.16% down from last year.
  • Per Anika Therapeutics' latest filing, its Equity Ratio stood at 0.76 for FY2024, which was down 3.16% from 0.78 recorded in FY2023.
  • Anika Therapeutics' 5-year Equity Ratio high stood at 0.83 for FY2021, and its period low was 0.75 during FY2020.
  • Over the past 3 years, Anika Therapeutics' median Equity Ratio value was 0.78 (recorded in 2023), while the average stood at 0.79.
  • As far as peak fluctuations go, Anika Therapeutics' Equity Ratio declined by 14.56% in 2020, and later increased by 10.87% in 2021.
  • Anika Therapeutics' Equity Ratio (Yearly) stood at 0.75 in 2020, then grew by 10.87% to 0.83 in 2021, then fell by 0.98% to 0.82 in 2022, then declined by 4.11% to 0.78 in 2023, then fell by 3.16% to 0.76 in 2024.